title: RNA: the new revolution in nucleic acid vaccines.
abstract: Nucleic acid vaccines have the potential to address issues of safety and effectiveness sometimes associated with vaccines based on live attenuated viruses and recombinant viral vectors. In addition, methods to manufacture nucleic acid vaccines are suitable as generic platforms and for rapid response, both of which will be very important for addressing newly emerging pathogens in a timely fashion. Plasmid DNA is the more widely studied form of nucleic acid vaccine and proof of principle in humans has been demonstrated, although no licensed human products have yet emerged. The RNA vaccine approach, based on mRNA and engineered RNA replicons derived from certain RNA viruses, is gaining increased attention and several vaccines are under investigation for infectious diseases, cancer and allergy. Human clinical trials are underway and the prospects for success are bright.
authors.affiliation: Novartis Vaccines & Diagnostics, Cambridge, MA 02139, USA. andrew.geall@novartis.com
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Geall
authors.forename: Christian W
authors.initials: CW
authors.lastname: Mandl
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Ulmer
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D005818:Genetic Engineering; D006801:Humans; D010957:Plasmids / Q000235:genetics; D012367:RNA, Viral / Q000235:genetics; D019444:Vaccines, DNA
chemical_list: D012367:RNA, Viral; D019444:Vaccines, DNA
keywords: Human; Manufacturing; Replicon; Safety; Stability